Kura Oncology Inc KURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
-
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
-
Kura Oncology to Participate in Cantor Global Healthcare Conference
-
Kura Oncology Reports Second Quarter 2024 Financial Results
-
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
-
Kura Oncology to Report Second Quarter 2024 Financial Results
-
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Trading Information
- Previous Close Price
- $18.18
- Day Range
- $18.03–18.65
- 52-Week Range
- $7.41–24.17
- Bid/Ask
- $18.03 / $19.15
- Market Cap
- $1.38 Bil
- Volume/Avg
- 452,400 / 583,372
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 142
- Website
- https://www.kuraoncology.com
Comparables
Valuation
|
Metric
|
KURA
|
ARTV
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.96 | — | 0.60 |
Price/Sales | — | 4.39 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
KURA
ARTV
PRLD
Financial Strength
|
Metric
|
KURA
|
ARTV
|
PRLD
|
|---|---|---|---|
Quick Ratio | 14.69 | 4.43 | 7.71 |
Current Ratio | 14.94 | 4.59 | 7.83 |
Interest Coverage | −124.90 | — | — |
Quick Ratio
KURA
ARTV
PRLD
Profitability
|
Metric
|
KURA
|
ARTV
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −30.27% | −16.21% | −40.98% |
Return on Equity (Normalized) | −33.34% | — | −46.70% |
Return on Invested Capital (Normalized) | −36.10% | — | −44.57% |
Return on Assets
KURA
ARTV
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hjpbkbqkr | Hyn | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lmhjnhrmv | Sswykw | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nlbdkdfxb | Qdcmnrg | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yffywcvk | Hrwklsp | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Dbqtblbt | Snb | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Tpbvrnhvf | Pckd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wzlpvqr | Fsd | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Pwbpnqm | Jjmpr | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bjplxnrd | Bxqxwt | $13.2 Bil | |||
| Incyte Corp
INCY
| Kjqsfcvm | Tmndzdx | $13.0 Bil |
United States